Living with Hemophilia A: Managing Daily Challenges and Improving Quality of Life

Living with a rare genetic disorder like Hemophilia A presents unique challenges, not only medically but also in navigating daily life and maintaining a good quality of life. Hemophilia A is a condition where the blood does not clot properly due to a deficiency in factor VIII, a crucial clotting protein. This can lead to spontaneous bleeding or excessive bleeding after injury, most often into joints and muscles. While it is a lifelong condition, significant advancements in treatment and care have transformed the outlook for individuals with Hemophilia A, enabling many to lead fuller, more active lives than ever before.

Understanding the impact of Hemophilia A on daily living and quality of life is essential for patients, caregivers, and healthcare providers. This article explores the common challenges faced and the strategies available to manage them effectively.

How Hemophilia A Affects Daily Life

The defining characteristic of Hemophilia A is the risk of bleeding. These bleeding episodes, particularly into joints (hemarthrosis), can significantly impact daily activities.

• Pain and Mobility Issues: Bleeds, especially joint bleeds, are often painful. Repeated bleeds into the same joint can lead to chronic joint damage, a condition known as hemophilic arthropathy. This can cause persistent pain, stiffness, and limited range of motion, making everyday tasks, work, and physical activities difficult. A study focusing on individuals in Colombia found that acute pain was the most frequently reported symptom, with many patients experiencing difficulty with activities of daily living (Torres et al., 2023).
• Risk of Bleeding: Even with treatment, the constant awareness of the risk of bleeding can influence lifestyle choices. Patients and caregivers may feel hesitant about participating in certain activities, impacting social engagement and independence.
• Treatment Burden: The traditional mainstay of treatment involves regular infusions of factor VIII concentrate to prevent bleeding (prophylaxis). While life-saving, the need for frequent intravenous injections can be time-consuming and challenging to manage, affecting schedules and potentially causing anxiety or discomfort.
• Psychological and Social Impact: Living with a chronic, rare condition can also have emotional and social consequences. Patients may experience anxiety, worry, or feel different from their peers. Lack of public and even healthcare provider knowledge about rare conditions can lead to misunderstandings and challenges in social and healthcare settings (von der Lippe et al., 2017).

The Impact on Quality of Life

Quality of life encompasses a person's overall well-being, including their physical health, psychological state, social relationships, and ability to perform daily activities. Hemophilia A has historically had a high impact on quality of life, and in some healthcare systems, it is recognized as having a significant economic impact due to the cost of care (Supporting Info).

However, major strides in treatment have dramatically improved the quality of life for many individuals with Hemophilia A.

• Prophylaxis: A Game Changer: The widespread adoption of prophylactic treatment, where factor concentrate is infused regularly to prevent bleeds, has revolutionized hemophilia care. By preventing bleeds, prophylaxis significantly reduces joint damage, chronic pain, and disability, thereby improving physical function and overall well-being (Franchini & Mannucci, 2012; Berntorp et al., 2021). Studies have shown that prophylaxis can lead to clinically meaningful improvements in health-related quality of life (O'Mahony et al., 2023).
• Reduced Treatment Burden: Newer treatments, such as extended half-life factor concentrates and non-factor replacement therapies administered less frequently or subcutaneously, are further reducing the burden of treatment. Extended half-life factor VIII, for example, can decrease the frequency of infusions, potentially increasing adherence and improving quality of life, especially for active individuals (Ozelo et al., 2024).
• Increased Life Expectancy and Near-Normal Lifestyle: With effective treatment and comprehensive care, individuals with Hemophilia A can now expect to live a near-normal lifespan and pursue many of the same educational, career, and recreational goals as their peers without the condition (Franchini & Mannucci, 2012; Berntorp et al., 2021).

Despite these advancements, challenges remain. The development of inhibitors (antibodies that make treatment less effective) can complicate care and impact quality of life. Chronic joint damage acquired before effective prophylaxis was available can also continue to cause pain and limit mobility.

Strategies for Managing Daily Life and Improving Quality of Life

Living well with Hemophilia A involves a proactive and comprehensive approach.

• Adherence to Treatment: Consistently following the prescribed treatment plan, especially prophylaxis, is the cornerstone of managing Hemophilia A and preventing complications that negatively impact daily life and quality of life.
• Comprehensive Care: Receiving care at a specialized Hemophilia Treatment Center (HTC) is crucial. These centers offer multidisciplinary teams, including hematologists, nurses, physical therapists, social workers, and psychologists, who can address the diverse needs of patients. Multidisciplinary care is essential for managing complications like hemophilic arthropathy and ensuring holistic well-being (Gualtierotti et al., 2021).
• Physical Activity: Regular exercise is important for building strong muscles around joints, maintaining a healthy weight, and improving overall physical and mental health. With appropriate precautions and consultation with the care team, individuals with Hemophilia A can safely participate in many types of physical activity tailored to their condition and joint status (Bertamino et al., 2017).
• Pain Management: Managing pain, whether acute from a bleed or chronic from joint damage, is a key component of improving quality of life. This can involve various strategies, including medication (like COX-2 inhibitors such as etoricoxib, as mentioned in research on pain management, though specific medications should always be discussed with a doctor), physical therapy, and other pain relief techniques.
• Patient Education and Empowerment: Understanding Hemophilia A, its potential complications, and treatment options empowers patients and caregivers to actively participate in their care. Shared decision-making with healthcare providers ensures that treatment plans align with individual needs, preferences, and lifestyle goals (Wang et al., 2022; Hermans et al., 2022).
• Psychological Support: Addressing the emotional impact of living with a chronic condition is vital. Counseling, support groups, and connecting with other individuals and families affected by hemophilia can provide valuable emotional support and coping strategies.

The Future Holds Promise

The landscape of hemophilia care continues to evolve rapidly. Ongoing research into novel therapies, including gene therapy and other non-factor treatments, holds the potential to further reduce treatment burden, prevent bleeds more effectively, and address existing complications. These advancements offer hope for even greater improvements in the daily lives and quality of life for future generations living with Hemophilia A.

In conclusion, while Hemophilia A presents significant challenges related to bleeding, pain, and the demands of treatment, modern care strategies, particularly prophylaxis and comprehensive care, have dramatically improved outcomes. By actively managing the condition, partnering with a dedicated healthcare team, and leveraging new therapeutic options as they emerge, individuals with Hemophilia A can navigate daily challenges and achieve a high quality of life.

References

• Alzahrani, H. A., Warsi, A., Mullah-Ali, A., Alotaibi, G., Abu-Riash, M., Alshahrani, M., ... & Hashmi, S. (2025). Consensus-Based Expert Recommendations on the Management of Hemophilia A in the Gulf Region. Hemoglobin, 49(1), 1-11.
• Berntorp, E., Fischer, K., Hart, D. P., Mancuso, M. E., Stephensen, D., Shapiro, A. D., & Blanchette, V. (2021). Haemophilia. Nature Reviews Disease Primers, 7(1), 1-18.
• Bertamino, M., Riccardi, F., Banov, L., Svahn, J., & Molinari, A. C. (2017). Hemophilia Care in the Pediatric Age. Italian Journal of Pediatrics, 43(1), 1-9.
• Castaman, G. (2018). The benefits of prophylaxis in patients with hemophilia B. Expert Review of Hematology, 11(11), 883-890.
• Franchini, M., & Mannucci, P. M. (2012). Past, present and future of hemophilia: a narrative review. Orphanet Journal of Rare Diseases, 7(1), 1-8.
• Gebetsberger, J., Schirmer, M., Wurzer, W. J., & Streif, W. (2022). Low Bone Mineral Density in Hemophiliacs. Hamostaseologie, 42(02), 130-136.
• Germini, F., Noronha, N., Abraham Philip, B., Olasupo, O., Pete, D., Navarro, T., ... & Iorio, A. (2022). Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature. Research and Practice in Thrombosis and Haemostasis, 6(1), e12640.
• Gualtierotti, R., Solimeno, L. P., & Peyvandi, F. (2021). Hemophilic arthropathy: Current knowledge and future perspectives. Journal of Clinical Medicine, 10(12), 2674.
• Hermans, C., Noone, D., Benson, G., Dolan, G., Eichler, H., Jiménez-Yuste, V., ... & Mancuso, M. E. (2022). Hemophilia treatment in 2021: Choosing the" optimal" treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians. European Journal of Haematology, 108(5), 373-388.
• Kruse-Jarres, R., Kempton, C. L., Baudo, F., Collins, P. W., Knoebl, P., Leissinger, C. A., ... & Kessler, C. M. (2017). Acquired hemophilia A: Updated review of evidence and treatment guidance.